The online version of this article (doi:10.1186/s12943-017-0647-2) contains supplementary material, which is available to authorized users.
Gastric cancer (GC) is one of the frequent causes of cancer-related death in eastern Asian population. IGF2BP2 lists in the top rank up-regulated genes in GC, but its functional role is unclear.
The expression of IGF2BP3 in GC cell lines and primary samples was examined by qRT-PCR and Western blot. The biological role of IGF2BP3 was revealed by a series of functional in vitro studies. Its regulation by microRNAs (miRNAs) was predicted by TargetScan and confirmed by luciferase assays and rescue experiments.
IGF2BP3 ranked the No.1 of the up-regulated genes by expression microarray analysis in GC cell lines. The expression level of IGF2BP3 was observed in GC tissues comparing with non-tumorous gastric epitheliums. The up-regulated IGF2BP3 expression was associated with poor disease specific survival. IGF2BP3 knockdown significantly inhibited cell proliferation and invasion. Apart from copy number gain, IGF2BP3 has been confirmed to be negatively regulated by tumor-suppressive miRNA, namely miR-34a. The expression of miR-34a showed negative correlation with IGF2BP3 mRNA expression in primary GC samples and more importantly, re-overexpression of IGF2BP3 rescued the inhibitory effect of miR-34a.
We compressively revealed the oncogenic role of IGF2BP3 in gastric tumorigenesis and confirmed its activation is partly due to the silence of miR-34a. Our findings identified useful prognostic biomarker and provided clinical translational potential.
Additional file 1: Table S1. Oligonucleotides used in the luciferase activity experiments. The oligonucleotides were annealed and subcloned into pMIR-REPORT via HindIII and SpeI restriction sites. WT (Wild type), full length of the putative miRNA binding site; Mutation, the binding site was mutated. (DOC 34 kb)12943_2017_647_MOESM1_ESM.doc
Additional file 2: Table S2. Expression microarray. (XLS 4646 kb)12943_2017_647_MOESM2_ESM.xls
Additional file 3: Figure S1. The correlation of IGF2BP3 copy number changes with it mRNA expression in primary GC samples (*, P < 0.05; TCGA cohort). (TIF 1399 kb)12943_2017_647_MOESM3_ESM.tif
Additional file 4: Table S3. Statistical results of IGF2BP3 survival curve analyzed by KM Plotter ( https://kmplot.com) (sig, significantly; CI, confident interval). (DOCX 14 kb)
Additional file 5: Table S4. Correlation of IGF2BP3 expression in GC with other clinicopathologic features (significant P-value in bold and Italic format). The case number and percentage counted were shown in the table. (DOC 64 kb)12943_2017_647_MOESM5_ESM.doc
Additional file 6: Table S5. Univariate and multivariate Cox regression analysis of the association between clinicopathologic characteristics and disease specific survival in patients with gastric adenocarcinoma (n = 247, significant P-value in bold and Italic format). (DOC 35 kb)12943_2017_647_MOESM6_ESM.doc
Additional file 7: Table S6. Statistical results of miR-34a survival curve derived from TCGA (sig, significantly; CI, confident interval). (DOCX 15 kb)12943_2017_647_MOESM7_ESM.docx
Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31–49. PubMed
The Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. CrossRef
Kang W, Tong JH, Chan AW, Zhao J, Dong Y, Wang S, Yang W, Sin FM, Ng SS, Yu J, et al. Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. J Transl Med. 2014;12:80. CrossRefPubMedPubMedCentral
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:1. CrossRef
Gene Ontology C. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43:D1049–56. CrossRef
Anaya J. OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. Peer J Pre Prints. 2016;4:e1780v–1v. CrossRef
Suvasini R, Shruti B, Thota B, Shinde SV, Friedmann-Morvinski D, Nawaz Z, Prasanna KV, Thennarasu K, Hegde AS, Arivazhagan A, et al. Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem. 2011;286:25882–90. CrossRefPubMedPubMedCentral
Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gulla A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, et al. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int. 2014;2014:217365. CrossRefPubMedPubMedCentral
Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gulla A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, et al. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. Plos One. 2014;9:e90005. CrossRefPubMedPubMedCentral
- IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis
Ho Lam Siu
Chi Chun Wong
William K. K. Wu
Alfred S. L. Cheng
Ka Fai To
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II